CARSGEN-B (02171) will present the research results of CT0596 and CT1190B at the EHA annual meeting in 2026.

CARSGEN-B (02171) announced that the research results of CT0596 (a universal CAR-T cell product targeting BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL), and CT1190B (a universal CAR-T cell product targeting CD19/CD20) for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have been presented as poster presentations at the 2026 European Hematology Association (EHA) Annual Meeting. The updated results of CT0596 were presented as a poster presentation at the EHA Annual Meeting on June 12, 2026, from 18:45 to 19:45 Central European Summer Time, with the title "First-in-Human Study of CT0596, an allogeneic BCMA CAR T in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell Leukemia: Safety, Efficacy, and Pharmacokinetic at Recommended Dose". The updated results of CT1190B were presented as a poster presentation at the EHA Annual Meeting on June 13, 2026, from 18:45 to 19:45 Central European Summer Time, with the title "First in Human Study of CT1190B, an Allogeneic Anti-CD19/CD20 CAR T-cell therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma".